SUN-PO094: The Role of Nutritional Interventions in Surgically Treated Pancreatic Cancer Patients: Comparative Efficacy in a Network Meta-Analysis (NMA)

This study evaluates the prognostic role of carbohydrate antigen 19 to 9 (CA19-9) in predicting survival of pancreatic cancer patients. Literature search was conducted in electronic databases (Google Scholar, Ovid, PubMed, and Science Direct) and study selection was based on precise eligibility criteria. Random-effects meta-analyses were performed to achieve overall estimates of median survival and hazard ratios (HRs) of survival with cutoff defined lower and higher CA19-9 levels before and after surgery or chemotherapy (CT)/radiotherapy (RT) and the changes in CA19-9 levels after any treatment. A total of 41 studies (6519 patients; 42% females; age 63.3 years [95% confidence interval [CI]: 62.2, 64.4]) were included. A pooled HR of 1.79 with a narrow 95% CI (1.58, 2.01) showed that higher CA19-9 levels or less decrease in CA19-9 levels after treatment predicted shorter survival. Median survival in patients with lower and higher preoperative CA19-9 levels was 23.2 months [95% CI: 17.2, 29.2] and 14.0 months [95% CI: 10.9, 17.2], respectively, whereas median survival with lower and higher postoperative CA19-9 levels was 25.0 months [95% CI: 21.9, 28.0] and 13.0 months [95% CI: 10.9, 15.0] respectively. Median survival with lower and higher pre-CT/RT CA19-9 levels was 11.9 months [95% CI: 10.2, 13.6] and 7.7 months [95% CI: 6.2, 9.2], respectively, whereas median survival with lower and higher post-CT/RT CA19-9 levels was 15.1 months [95% CI: 13.2, 17.0] and 10.7 months [95% CI: 7.3, 14.0] respectively. A decrease in CA19-9 levels after treatment was also associated with longer survival. Thus, both pretreatment and posttreatment CA19-9 levels or their changes after treatment have good prognostic value in determining the survival of pancreatic cancer patients.

Download Full-text

The role of maintenance therapy in the treatment of elderly non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials [Corrigendum]

Drug Design Development and Therapy ◽

10.2147/dddt.s162571 ◽

2018 ◽

Vol Volume 12 ◽

pp. 391-392

Author(s):

Liangze Zhang ◽

Shugeng Gao ◽

Jie He

Keyword(s):

Lung Cancer ◽

Maintenance Therapy ◽

Cancer Patients ◽

Meta Analysis ◽

Small Cell ◽

Controlled Trials ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Randomized Controlled

Download Full-text

Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus

Clinical & Translational Oncology ◽

10.1007/s12094-021-02674-x ◽

2021 ◽

Author(s):

A. Carrato ◽

L. Cerezo ◽

J. Feliu ◽

T. Macarulla ◽

E. Martín-Pérez ◽

...

Keyword(s):

Pancreatic Cancer ◽

Cancer Patients ◽

Clinical Outcomes ◽

Health Care Professionals ◽

Unmet Need ◽

Screening Tools ◽

Therapeutic Management ◽

Care Process ◽

Nutritional Screening

Abstract Purpose Malnutrition is a common problem among pancreatic cancer (PC) patients that negatively impacts on their quality of life (QoL) and clinical outcomes. The main objective of this consensus is to address the role of Medical Nutrition Therapy (MNT) into the comprehensive therapeutic management of PC patients. Methods A Spanish multidisciplinary group of specialists from the areas of Medical Oncology; Radiation Oncology; Endocrinology and Nutrition; and General Surgery agreed to assess the role of MNT as part of the best therapeutic management of PC patients. Results The panel established different recommendations focused on nutritional screening and nutritional screening tools, MNT strategies according to PC status, and MNT in palliative treatment. Conclusions There is an unmet need to integrate nutritional therapy as a crucial part of the multimodal care process in PC patients. Health authorities, health care professionals, cancer patients, and their families should be aware of the relevance of nutritional status and MNT on clinical outcomes and QoL of PC patients.

Download Full-text

Prognostic Role of miR-221 and miR-222 Expression in Cancer Patients: A Systematic Review and Meta-Analysis

Cancers ◽

10.3390/cancers11070970 ◽

2019 ◽

Vol 11 (7) ◽

pp. 970 ◽

Cited By ~ 5

Author(s):

Gloria Ravegnini ◽

Sarah Cargnin ◽

Giulia Sammarini ◽

Federica Zanotti ◽

Justo Lorenzo Bermejo ◽

...

Keyword(s):

Systematic Review ◽

Cancer Patients ◽

Meta Analysis ◽

Fine Tuning ◽

High Expression ◽

Cochrane Library ◽

Published Data ◽

Significant Heterogeneity ◽

Free Survival

Background: A wealth of evidence has shown that microRNAs (miRNAs) can modulate specific genes, increasing our knowledge on the fine-tuning regulation of protein expression. miR-221 and miR-222 have been frequently identified as deregulated across different cancer types; however, their prognostic significance in cancer remains controversial. In view of these considerations, we performed an updated systematic review and meta-analysis of published data investigating the effects of miR-221/222 on overall survival (OS) and other secondary outcomes among cancer patients. A systematic search of PubMed, Web of Knowledge, and Cochrane Library databases was performed. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to assess the strength of association. Results: Fifty studies, analyzing 6086 patients, were included in the systematic review. Twenty-five studies for miR-221 and 17 studies for miR-222 which assessed OS were included in the meta-analysis. High expression of miR-221 and miR-222 significantly predicted poor OS (HR: 1.48, 95% CI: 1.14–1.93, p = 0.003 and HR: 1.90, 95% CI: 1.43–2.54, p < 0.001, respectively). Subgroup analysis revealed that the finding on miR-221 was not as robust as the one on miR-222. Furthermore, high miR-222 expression was also associated with worse progression-free survival and disease-free survival pooled with recurrence-free survival. Conclusions: The meta-analysis demonstrated that high expression of miR-222 is associated with poor prognosis in cancer patients, whereas the significance of miR-221 remains unclear. More work is required to fully elucidate the role of miR-221 and miR-222 in cancer prognosis, particularly in view of the limitations of existing results, including the significant heterogeneity and limited number of studies for some cancers.

Download Full-text

MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential

Genes ◽

10.3390/genes10100752 ◽

2019 ◽

Vol 10 (10) ◽

pp. 752 ◽

Cited By ~ 11

Author(s):

Rawat ◽

Kadian ◽

Gupta ◽

Kumar ◽

Chain ◽

...

Keyword(s):

Pancreatic Cancer ◽

Cancer Patients ◽

Therapeutic Potential ◽

Critical Role ◽

Mirna Biogenesis ◽

Effective Management ◽

Future Directions ◽

Novel Therapeutic Strategies ◽

Conclusion Section

Pancreatic cancer is one of the most aggressive malignancies, accounting for more than 45,750 deaths annually in the U.S. alone. The aggressive nature and late diagnosis of pancreatic cancer, coupled with the limitations of existing chemotherapy, present the pressing need for the development of novel therapeutic strategies. Recent reports have demonstrated a critical role of microRNAs (miRNAs) in the initiation, progression, and metastasis of cancer. Furthermore, aberrant expressions of miRNAs have often been associated with the cause and consequence of pancreatic cancer, emphasizing the possible use of miRNAs in the effective management of pancreatic cancer patients. In this review, we provide a brief overview of miRNA biogenesis and its role in fundamental cellular process and miRNA studies in pancreatic cancer patients and animal models. Subsequent sections narrate the role of miRNA in, (i) cell cycle and proliferation; (ii) apoptosis; (iii) invasions and metastasis; and (iv) various cellular signaling pathways. We also describe the role of miRNA’s in pancreatic cancer; (i) diagnosis; (ii) prognosis and (iii) therapeutic intervention. Conclusion section describes the gist of review with future directions.

Download Full-text

Prognostic role of long noncoding RNA ZFAS1 in cancer patients: a systematic review and meta-analysis

Oncotarget ◽

10.18632/oncotarget.19162 ◽

2017 ◽

Vol 8 (59) ◽

pp. 100490-100498 ◽

Cited By ~ 8

Author(s):

Tian Lan ◽

Xiong Lan ◽

Guangcai Li ◽

Zhen Zheng ◽

Minghua Zhang ◽

...

Keyword(s):

Systematic Review ◽

Cancer Patients ◽

Long Noncoding Rna ◽

Noncoding Rna ◽

Meta Analysis ◽

Prognostic Role

Download Full-text

Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis

Disease Markers ◽

10.1155/2019/8632018 ◽

2019 ◽

Vol 2019 ◽

pp. 1-12 ◽

Cited By ~ 3

Author(s):

Shree Ram Lamichhane ◽

Thanuja Thachil ◽

Harriet Gee ◽

Natalie Milic

Keyword(s):

Systematic Review ◽

Overall Survival ◽

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Meta Analysis ◽

Prognostic Role ◽

Circulating Micrornas

Background. Circulating microRNAs (miRNAs) are potential molecular biomarkers for cancer detection; however, little is known about their prognostic role in head and neck cancer. This current study is aimed at evaluating the role of novel miRNAs in the survival of head and neck cancer patients. Materials and Methods. We performed a systematic literature search using online databases for articles published between December 2006 and February 2019. A meta-analysis was conducted to assess the correlation between miRNA expressions and overall survival (OS) among the selected head and neck cancer studies. After multilevel screening by reviewers, meta-analysis was performed using hazard ratios (HR) and associated 95% confidence interval (CI) of survival to calculate a pooled effect size. Result. A total of 1577 patients across 13 studies were included in the literature review, with 18 miRNAs upregulated and 4 miRNAs downregulated predicting a poor overall survival. The forest plot generated using cumulated survival data resulted in a pooled HR value of 2.943 (95% CI: 2.394-3.618) indicating a strong association of dysregulated miRNA expression with a poor outcome. Only 2 miRNAs—low levels of miR-9 and high levels of miR-483-5p—were observed in two studies, both showing a significant association with overall cancer survival. Conclusion. To our knowledge, this is the first comprehensive systematic review and meta-analysis that examines the prognostic role of circulating miRNAs from blood in head and neck cancer patients. The combined effect estimates a HR across multiple studies and also supports the previous individual findings that an alteration in miRNA expression is highly associated with poor prognosis. This has the potential to use serum and/or plasma miRNAs as biomarkers and become novel tools for predicting the prognosis of head and neck cancer patients in the near future.

Download Full-text